London, UK; 14 March 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: “GWP,” “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces the positive results of the first pivotal Phase 3 study of its investigational medicine Epidiolex® (cannabidiol or CBD) for [...]
The Epilepsy Foundation of America has started a petition on the White House website. We need your help! We are calling on the President and the Drug Enforcement Administration to reschedule marijuana to a lower level under the controlled substances act. The Foundation supports this change to benefit greater access to marijuana and its [...]
DEERFIELD, Ill.--(BUSINESS WIRE)--Lundbeck announced today that ONFI Tablets are now available for prescribing in the United States. The FDA recently approved ONFI for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients two years and older.1 ONFI is an oral anti-epileptic drug (AED) of the benzodiazepine class, and is a 1,5 benzodiazepine.1 ONFI [...]
Drug Shortage Alert: Pfizer Announces DILANTIN® 30 mg (Extended Phenytoin Sodium Capsules, USP) Shortage The Epilepsy Foundation has learned that Pfizer is contacting health care professionals, including pharmacists, about a shortage of DILANTIN 30 mg. According to Pfizer, this product shortage is due to a manufacturing issue and not the result of any performance or [...]
